Products from BPS Bioscience require a minimum order value above 400€
Application: Useful for studying the binding and neutralization of IL-33 (Interleukin-33) interaction with IL-1RL1 in ELISA and in cellular assays.
Assay Conditions: This antibody was tested with a method adapted from IL1RL1:IL33 [Biotinylated] Inhibitor Screening Chemiluminescence Assay Kit (#82856). A serial dilution of Anti-IL-33 Neutralizing Antibody at 1:3 starting with a final concentration of 10 nM was prepared in 1x PP-02 buffer.
Background: IL-33 is a cytokine of the IL-1 family that is released in response to external triggers, such as trauma, allergen exposure and infections. IL-33 can be either in a reduced or oxidized state, which use different signaling pathways. When in its reduced state (IL-33red) it binds to IL-1RL1 ((interleukin 1 receptor like 1), also named IL-33R or ST2 (receptor serum-stimulated 2). IL-1RL1 exists as both a membrane bound protein or a truncated soluble form. Binding of IL-33 to IL-1RL1 initiates a signaling pathway that involves NF-κF (nuclear factor kappa-light-chain-enhancer of activated B cells) and MAPK (mitogen-activated protein kinase), and results in release of pro-inflammatory cytokine and chemokines. The soluble form of IL-1RL1 can act as a decoy receptor for IL-33. Dysregulation in the levels of IL-33 is implicated in the pathology of inflammatory and infectious diseases, including COVID-19, COPD (chronic obstructive pulmonary disease) and asthma. The involvement of IL-33 in these diseases has made it a high value therapeutic target, with strategies such as antibodies being developed to inhibit the binding of IL-33 to its receptor. One example is Tozorakimab (MEDI3506), from AstraZeneca, currently being evaluated as treatment for COPD. Further studies on IL-33 and its receptor will likely result in new therapies for IL-33 related disorders.
Description: This anti-IL-33 antibody is a purified, humanized recombinant monoclonal antibody that recognizes human IL-33 (Interleukin-33). This antibody has been tested for neutralization of IL-33 (Interleukin-33) interaction with IL-1RL1 (interleukin 1 receptor like 1 or IL-33R) in a binding assay. This antibody is similar to Tozorakimab.
Endotoxin Level: 3.7 EU/mg
Format: Aqueous buffer solution.
Formulation: 8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
Host Cell Line: HEK293
Purity: ≥85%
Storage Stability: At least 6 months at -80°C.
Target: IL-33
Uniprot: O95760
Warnings: Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
Deutsch
English
